CNS Pharma targets oncology, neurology in-licensing to build new therapy pipeline

• CNS Pharmaceuticals outlined a strategy to build a pipeline in oncology or neurology, targeting assets with best-in-class potential.
• Near-term focus on executing business development plans through in-licensing or acquisitions to expand its portfolio.
• Screening process prioritizes scientific, clinical, regulatory, commercial fit to support long-term shareholder value creation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609010901ACCESSWRNAPR_____1214888) on September 01, 2026, and is solely responsible for the information contained therein.